ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

molnupiravir

Also written as “Molnupiravir”, “EIDD-2801” and “MK-4482”.

Its studies are mostly in COVID-19 · Renal Insufficiency · Coronavirus Infections, led by 4 companies.

Drug pageMolnupiravir: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 30, 202014 company-led studies, 1 open or runningNext primary completion: Jan 26, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck91 open or runningphase 3since Sep 30, 2020Sep 30, 2020Jan 26, 2031phase 3 · NCT06667700
Ridgeback Biotherapeutics, LPits history only30 open or runningphase 2since May 26, 2020Apr 29, 2020none ahead
Geropharmits history only10 open or runningno phasesince Dec 7, 2022Dec 7, 2022none ahead
Valenta Pharm JSCits history only10 open or runningno phasesince Jun 6, 2022Jun 6, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2020First studies: 2 phase 3 studies in COVID-19First studyNCT04575597, NCT04575584
  2. Dec 19, 2020Named molnupiravirINNProposed as its International Nonproprietary Name in WHO's List 124 · before, EIDD-2801, MK-4482
  3. Jun 24, 2021Phase 3 study in COVID-19NCT04939428 · 2,441 enrolled · United States, Argentina, Brazil and more
  4. May 18, 20222 phase 1 studiesNCT05386758, NCT05386589
  5. Sep 26, 2022Phase 2 study in Respiratory Syncytial VirusNCT05559905 · 116 enrolled · United Kingdom
  6. Sep 24, 2024Phase 1 study in HealthyNCT06615869 · 64 enrolled · United States
  7. Oct 30, 2024Phase 3 study in COVID-19NCT06667700 · 3,082 planned · United States, Argentina, Brazil and more
  8. Feb 4, 2025Phase 1 study in COVID-19NCT06816030 · 16 enrolled · China

Ahead

  1. Jan 26, 2031Primary completion: phase 3 study in COVID-19NCT06667700

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RNA disrupting agent”ChEMBL 37, by rule

Studies

All 9 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06816030COVID-19 · China1CompletedAug 5, 202316
NCT06667700COVID-19 · United States, Argentina, Brazil and more3RecruitingJan 26, 20313,082
NCT06615869Healthy · United States1CompletedFeb 27, 202364
NCT05559905Respiratory Syncytial Virus · United Kingdom2CompletedApr 18, 2023116
NCT05386758Renal Insufficiency · United States1CompletedFeb 4, 202316
NCT05386589Hepatic Impairment · United States1CompletedDec 18, 202214
NCT04939428COVID-19 · United States, Argentina, Brazil and more3CompletedNov 16, 20222,441
NCT04575597COVID-19 · United States, Argentina, Brazil and more3CompletedMay 5, 20221,735
NCT04575584COVID-19 · United States, Brazil, Canada and more3TerminatedAug 11, 2021304

How it is read

Names in the registry

  • “Molnupiravir”, 9 entries
  • “EIDD-2801”, 2 entries
  • “MK-4482”, 1 entry
  • “GP30341 capsules 200 mg”, 1 entry
  • “Molnupiravir 200 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.